Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause

Atherosclerosis

Volumn 254, Issue , 2016, Pages 282-290

  Lobo, Roger A ^a   Pickar, James H ^a   Stevenson, John C ^b   Mack, Wendy J ^c   Hodis, Howard N ^c  

^a Columbia University ^*  (United States)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Coronary heart disease; Estrogen; Hormone replacement therapy; Menopause; Mortality; Prevention

Indexed keywords

CALCIUM; ESTROGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGE DISTRIBUTION; ARTERIAL WALL THICKNESS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAROTID ARTERY; CHRONIC DISEASE; CORONARY ARTERY; FEMALE; FRACTURE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSE; META ANALYSIS (TOPIC); MORTALITY RISK; OBSERVATIONAL STUDY; PERSONALIZED MEDICINE; PHARMACOGENOMICS; POSTMENOPAUSE; PREVENTION STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; SYSTEMATIC REVIEW (TOPIC); AGED; BLOOD; BREAST TUMOR; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DRUG EFFECTS; ESTROGEN THERAPY; MALE; METHODOLOGY; MIDDLE AGED; OSTEOPOROSIS; PATHOLOGY; PROCEDURES; WOMEN'S HEALTH;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BREAST NEOPLASMS; CALCIUM; CAROTID INTIMA-MEDIA THICKNESS; CORONARY ARTERY DISEASE; CORONARY DISEASE; CORONARY VESSELS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT; WOMEN'S HEALTH;

EID: 84994301732     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.10.005     Document Type: Review

References (86)

1. [1] Stampfer, M.J., et al. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev. Med. 20 (1991), 47–63.
2. [2] Grodstein, F., et al. Postmenopausal hormone therapy and mortality. N. Engl. J. Med. 336 (1997), 1769–1775.
3. [3] Yaffe, K., et al. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 279 (1998), 688–695.
4. [4] Henderson, B.E., et al. Decreased mortality in users of estrogen replacement therapy. Arch. Intern Med. 151 (1991), 75–78.
5. [5] Grady, D., et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern Med. 117 (1992), 1016–1037.
6. [6] American College of Physicians, Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann. Intern. Med. 117 (1992), 1038–1041.
7. [7] Hulley, S., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998), 605–613.
8. [8] Clarke, S.C., et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG 109 (2002), 1056–1062.
9. [9] Writing Group for the Women's Health Initiative Investigators, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002), 321–333.
10. [10] Lobo, R.A., et al. Prevention of diseases after menopause. Climacteric 17 (2014), 540–556.
11. [11] Lobo, R.A., et al. Too much of a good thing? Use of progestogens in the menopause: an international consensus statement. Fertil. Steril. 51 (1989), 229–231.
12. [12] NHLBI stops trial of estrogen plus progestin due to increased breast cancer risk and lack of overall benefit. South Med. J. 95 (2002), 795–797.
13. [13] Stevenson, J.C., et al. Coronary heart disease and menopause management: the swinging pendulum of HRT. Atherosclerosis 207 (2009), 336–340.
14. [14] Manson, J.E., et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 310 (2013), 1353–1368.
15. [15] Mikkola, T.S., et al. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J. Clin. Endocrinol. Metab. 100 (2015), 4588–4594.
16. [16] Islam, S., et al. Trend in incidence of osteoporosis-related fractures among 40 to 69 year old women: analysis of a large insurance claims database, 2000-2005. Menopause 16 (2009), 77–83.
17. [17] Karim, R., Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause 18 (2011), 1172–1177.
18. [18] Sarrel, P., et al. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women age 50 to 59. Am. J. Public Health 103 (2013), 1583–1588.
19. [19] Ravdin, P.M., et al. The decrease in incidence of breast cancer in the United States. Oestradiol NEJM 356:16 (2007), 1670–1674.
20. [20] Shapiro, S., et al. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 5. Secular trends. J. Fam. Plan. Reprod. Health Care 39 (2013), 80–88.
21. [21] Mendelsohn, M.E., et al. Molecular and cellular basis of cardiovascular gender differences. Science 308:5728 (2005), 1583–1587.
22. [22] Post, W.S., Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res. 43 (1999), 985–991.
23. [23] Umetani, M., 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat. Med. 13 (2007), 1185–1192.
24. [24] Eilertsen, A.L., et al. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. Maturitas 55 (2006), 278–287.
25. [25] Wingrove, C.S., et al. 17β-Oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim. Biophys. Acta 1406 (1998), 169–174.
26. [26] Hwang, J., Hodis, H.N., Hsiai, T.K., Asatryan, L., Sevanian, A., Role of annexin II in estrogen-induced macrophage matrix metalloproteinase-9 activity: the modulating effect of statins. Atherosclerosis 189 (2006), 76–82.
27. [27] Kindig, D.A., et al. Even as mortality fell in most US counties, female mortality nonetheless rose in 42.8 percent of counties from 1992 to 2006. Health Aff. (Millwood) 32:3 (2013), 451–458.
28. [28] Hodis, H.N., et al. The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women, Part 1: comparison of therapeutic efficacy. J. Am. Geriatr. Soc. 61 (2013), 1005–1010.
29. [29] Mikkola, T.S., et al. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause 22 (2015), 976–983.
30. [30] Tuomikoski, P., et al. Coronary heart disease mortality and hormone therapy before and after the Women's Health Initiative. Obstet. Gynecol. 124 (2014), 947–953.
31. [31] Tuomikoski, P., et al. The risk of fatal stroke in Finnish postmenopausal hormone therapy users before and after the Women's Health Initiative: a cohort study. Maturitas 81 (2015), 384–388.
32. [32] Mikkola, T.S., et al. Vaginal estradiol use and the risk for cardiovascular mortality. Hum. Reprod. 31 (2016), 804–809.
33. [33] Carrasquilla, G.D., et al. The association between menopausal hormone therapy and coronary heart disease depends on timing of initiation in relation to menopause onset: results based on pooled individual participant data from the Combined Cohorts of Menopausal Women – studies of Register Based Health Outcomes in Relation to Hormonal Drugs (COMPREHEND) study. Menopause, 22, 2015, 1373 Conference abstract S17.
34. [34] Grodstein, F., et al. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog. Cardiol. Dis. 38 (1995), 199–210.
35. [35] Grodstein, F., et al. Estrogen for women at varying risk of coronary disease. Maturitas 30 (1998), 19–26.
36. [36] Hodis, H.N., et al. A window of opportunity: the reduction of coronary heart disease and total mortality with menopausal therapies is age and time dependent. Brain Res. 1379 (2011), 244–252.
37. [37] Schierbeck, L.L., et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial. BMJ, 345, 2012, e6409.
38. [38] Rossouw, J.E., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297 (2007), 1465–1477.
39. [39] Hsia, J., et al., for the Women's Health Initiative Investigators, Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch. Intern Med. 166 (2006), 357–365.
40. [40] LaCroix, A.Z., et al., for the WHI Investigators, Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305 (2011), 1305–1314.
41. [41] Salpeter, S.R., et al. Brief report: coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J. Gen. Intern Med. 21 (2006), 363–366.
42. [42] Salpeter, S.R., et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J. Gen. Intern Med. 19 (2004), 791–804.
43. [43] Boardman, H.M.P., et al. Hormone therapy for preventing cardiovascular disease in postmenopausal women. Cochrane Database Syst. Rev., 2015, 10.1002/14651858.CD002229.pub4 Issue 3. Art. No.cD002229.
44. [44] Salpeter, S.R., et al. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am. J. Med. 122 (2009), 1016–1022.
45. [45] Tremollieres, F.A., et al. Effect of hormone replacement therapy on age-related increase in carotid artery intima-media thickness in postmenopausal women. Atherosclerosis 153 (2000), 81–88.
46. [46] Takahashi, K., et al. Long-term hormone replacement therapy delays the age related progression of carotid intima-media thickness in healthy postmenopausal women. Maturitas 49 (2004), 170–177.
47. [47] McGrath, B.P., et al. Age-related deterioration in arterial structure and function in postmenopausal women: impact of hormone replacement therapy. Arter. Thromb. Vas Biol. 18 (1998), 1149–1156.
48. [48] de Kleijn, M.J.J., et al. Hormone replacement therapy in perimenopausal women and 2-year change of carotid intima-media thickness. Maturitas 32 (1999), 195–204.
49. [49] Espeland, M.A., et al., for the ACAPS Investigators, Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. Am. J. Epidemiol. 142 (1995), 1011–1019.
50. [50] Hodis, H.N., et al., for the Estrogen in Prevention of Atherosclerosis Trial Research Group, Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann. Intern Med. 135 (2001), 939–953.
51. [51] Harman, S.M., et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann. Intern Med. 161 (2014), 249–260.
52. [52] Osteberg, J.E., et al. A dose-response study of hormone replacement in young hypogonadal women: effects on intima-media thickness and metabolism. Clin. Endocrinol. 66 (2007), 557–564.
53. [53] Hodis, H.N., et al. Effects of early versus late postmenopausal treatment with estradiol. N. Engl. J. Med., 374, 2016 12231–12231.
54. [54] Akhrass, F., et al. Hormone replacement therapy is associated with less coronary atherosclerosis in postmenopausal women. J. Clin. Endocrinol. Metab. 88 (2003), 5611–5614.
55. [55] Barrett-Connor, E., et al. Hormone therapy and coronary artery calcification in asymptomatic postmenopausal women: the Rancho Bernardo Study. Menopause 12 (2005), 40–48.
56. [56] Schisterman, E.F., et al. The association of hormone replacement therapy and coronary calcium as determined by electron beam tomography. J. Womens Health Gend. Based Med. 11 (2002), 631–638.
57. [57] Manson, J.E., et al., for the WHI and WHI-CACS Investigators, Estrogen therapy and coronary-artery calcification. N. Engl. J. Med. 356 (2007), 2591–2602.
58. [58] Walsh, J.M.E., et al. Drug treatment of hyperlipidemia in women. JAMA 291 (2004), 2243–2252.
59. [59] Petretta, M., et al. Impact of gender in primary prevention of coronary heart disease with stain therapy: a meta-analysis. Int. J. Cardiol. 138 (2010), 25–31.
60. [60] Brugts, J.J., et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials. BMJ, 338, 2009, b2376.
61. [61] Berger, J.S., et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295 (2006), 306–313.
62. [62] Ridker, P.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. 352 (2005), 1293–1304.
63. [63] Ogawa, H., et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300 (2008), 2134–2141.
64. [64] Wing, L.M.H., et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. 348 (2003), 585–592.
65. [65] Shekelle, P.G., et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J. Am. Coll. Cardiol. 41 (2003), 1529–1538.
66. [66] Yusuf, S., et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N. Engl. J. Med., 2015, April 2nd.
67. [67] Salpeter, S.R., et al. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am. J. Med. 122 (2009), 42–52.
68. [68] Avis, N.E., et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med., 2014, e1.
69. [69] Zhu, L., et al. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. Menopause 4 (2015), 461–470.
70. [70] Bagger, Y.Z., et al. Two to three years of hormone replacement treatment in healthy women have long term preventive effects on bone mass and osteoporotic fractures:the PERF Study. Bone 34 (2004), 728–735.
71. [71] Bagger, Y.Z., et al. Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause 12:1 (2005), 12–17.
72. [72] Bergendal, A., et al. Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri and postmenopausal women and in relation to type and route of administration. Menopause 23:6 (2016), 593–599.
73. [73] https://www.asc.org/irs/statinfo/.
74. [74] Bolland, M.J., et al. Vascular events in healthy older women receiving calcium supplementation: randomized controlled trial. BMJ 336 (2008), 262–266.
75. [75] Li, C.I., et al. Use of antihypertensive medications and breast Cancer risk among women aged 55 to 74 years. JAMA Intern Med. 173 (2013), 1629–1637.
76. [76] Gerstein, H.C., et al. Effects of intensive glucose lowering in Type 2 Diabetes. N. Engl. J. Med. 358 (2008), 2545–2549.
77. [77] Anderson, G.L., et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen and progestin. Maturitas 55 (2006), 107–115.
78. [78] Anderson, G.L., et al. Conjugated equine estrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomized placebo-controlled trial. Lancet Oncol. 13 (2012), 476–486.
79. [79] Stefanick, M.L., et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295 (2006), 1647–1657.
80. [80] Chen, W.Y., et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch. Intern Med., 166, 2006 1927–1032.
81. [81] Gompel, A., et al. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 15 (2012), 241–249.
82. [82] Fournier, A., et al. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res. Treat. 107 (2008), 103–111.
83. [83] Davis, S.R., et al. Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. Menopause 7 (2000), 395–401.
84. [84] Komm, B.S., et al. Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for 7:e3411 management of menopausal hot flashes and postmenopausal bone loss. Steroids 90 (2014), 71–81.
85. [85] Canonico, M., et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postme3nopausal women: impact of the route of administration and progestogens: the ESTER study. Circulation 115 (2007), 840–845.
86. [86] Manson, J.E., et al. Menopause management – getting clinical care back on track. N. Engl. J. Med. 374 (2016), 803–806.